ADC Therapeutics SA Net Income 2019-2022 | ADCT

ADC Therapeutics SA net income from 2019 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
ADC Therapeutics SA Annual Net Income
(Millions of US $)
2021 $-230
2020 $-246
2019 $-116
2018 $-123
ADC Therapeutics SA Quarterly Net Income
(Millions of US $)
2022-09-30 $-51
2022-06-30 $-64
2022-03-31 $-17
2021-12-31 $-34
2021-09-30 $-72
2021-06-30 $-73
2021-03-31 $-52
2020-12-31 $-56
2020-09-30 $-20
2020-06-30 $-127
2020-03-31 $-43
2019-12-31
2019-09-30 $-31
2019-06-30 $-23
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.359B $0.034B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00